Selected research
Market Structure
Global Pegfilgrastim Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Pegfilgrastim Biosimilar market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Pegfilgrastim Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Pegfilgrastim Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Pegfilgrastim Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Pegfilgrastim Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Pegfilgrastim Biosimilar include Biocon, Coherus BioSciences, Dr Reddy’s Laboratories, Intas Pharmaceuticals, Mundipharma International, Pfizer, Mylan and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Pegfilgrastim Biosimilar market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Pegfilgrastim Biosimilar and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Pegfilgrastim Biosimilar sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pegfilgrastim Biosimilar market size, projected growth trends, production technologies, key applications, and end-use industries.
Pegfilgrastim Biosimilar Segment by Company
Biocon
Coherus BioSciences
Dr Reddy’s Laboratories
Intas Pharmaceuticals
Mundipharma International
Pfizer
Mylan
Novartis
Pegfilgrastim Biosimilar Segment by Type
Chemotherapy Treatment
Transplantation
Pegfilgrastim Biosimilar Segment by Application
Mail-Order Pharmacies
Hospital Pharmacies
Retail Pharmacies
Pegfilgrastim Biosimilar Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pegfilgrastim Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pegfilgrastim Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pegfilgrastim Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Pegfilgrastim Biosimilar market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pegfilgrastim Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pegfilgrastim Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Pegfilgrastim Biosimilar in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Chemotherapy Treatment
- Transplantation
Applications
- Mail-Order Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Companies covered
- Biocon
- Coherus BioSciences
- Dr Reddy’s Laboratories
- Intas Pharmaceuticals
- Mundipharma International
- Pfizer
- Mylan
- Novartis
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Pegfilgrastim Biosimilar Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Pegfilgrastim Biosimilar Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Pegfilgrastim Biosimilar Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Pegfilgrastim Biosimilar Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Pegfilgrastim Biosimilar Market Dynamics
- 2.1 Pegfilgrastim Biosimilar Industry Trends
- 2.2 Pegfilgrastim Biosimilar Industry Drivers
- 2.3 Pegfilgrastim Biosimilar Industry Opportunities and Challenges
- 2.4 Pegfilgrastim Biosimilar Industry Restraints
3 Pegfilgrastim Biosimilar Market by Manufacturers
- 3.1 Global Pegfilgrastim Biosimilar Revenue by Manufacturers (2021-2026)
- 3.2 Global Pegfilgrastim Biosimilar Sales by Manufacturers (2021-2026)
- 3.3 Global Pegfilgrastim Biosimilar Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Pegfilgrastim Biosimilar Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Pegfilgrastim Biosimilar Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Pegfilgrastim Biosimilar Manufacturers, Product Type & Application
- 3.7 Global Pegfilgrastim Biosimilar Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Pegfilgrastim Biosimilar Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Pegfilgrastim Biosimilar Players Market Share by Revenue in 2025
- 3.8.3 2025 Pegfilgrastim Biosimilar Tier 1, Tier 2, and Tier 3
4 Pegfilgrastim Biosimilar Market by Type
- 4.1 Pegfilgrastim Biosimilar Type Introduction
- 4.1.1 Chemotherapy Treatment
- 4.1.2 Transplantation
- 4.2 Global Pegfilgrastim Biosimilar Sales by Type
- 4.2.1 Global Pegfilgrastim Biosimilar Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Pegfilgrastim Biosimilar Sales by Type (2021-2032)
- 4.2.3 Global Pegfilgrastim Biosimilar Sales Market Share by Type (2021-2032)
- 4.3 Global Pegfilgrastim Biosimilar Revenue by Type
- 4.3.1 Global Pegfilgrastim Biosimilar Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Pegfilgrastim Biosimilar Revenue by Type (2021-2032)
- 4.3.3 Global Pegfilgrastim Biosimilar Revenue Market Share by Type (2021-2032)
5 Pegfilgrastim Biosimilar Market by Application
- 5.1 Pegfilgrastim Biosimilar Application Introduction
- 5.1.1 Mail-Order Pharmacies
- 5.1.2 Hospital Pharmacies
- 5.1.3 Retail Pharmacies
- 5.2 Global Pegfilgrastim Biosimilar Sales by Application
- 5.2.1 Global Pegfilgrastim Biosimilar Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Pegfilgrastim Biosimilar Sales by Application (2021-2032)
- 5.2.3 Global Pegfilgrastim Biosimilar Sales Market Share by Application (2021-2032)
- 5.3 Global Pegfilgrastim Biosimilar Revenue by Application
- 5.3.1 Global Pegfilgrastim Biosimilar Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Pegfilgrastim Biosimilar Revenue by Application (2021-2032)
- 5.3.3 Global Pegfilgrastim Biosimilar Revenue Market Share by Application (2021-2032)
6 Global Pegfilgrastim Biosimilar Sales by Region
- 6.1 Global Pegfilgrastim Biosimilar Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Pegfilgrastim Biosimilar Sales by Region (2021-2032)
- 6.2.1 Global Pegfilgrastim Biosimilar Sales by Region (2021-2026)
- 6.2.2 Global Pegfilgrastim Biosimilar Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Pegfilgrastim Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Pegfilgrastim Biosimilar Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Pegfilgrastim Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Pegfilgrastim Biosimilar Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Pegfilgrastim Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Pegfilgrastim Biosimilar Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Pegfilgrastim Biosimilar Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Pegfilgrastim Biosimilar Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Pegfilgrastim Biosimilar Revenue by Region
- 7.1 Global Pegfilgrastim Biosimilar Revenue by Region
- 7.1.1 Global Pegfilgrastim Biosimilar Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Pegfilgrastim Biosimilar Revenue by Region (2021-2026)
- 7.1.3 Global Pegfilgrastim Biosimilar Revenue by Region (2027-2032)
- 7.1.4 Global Pegfilgrastim Biosimilar Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Pegfilgrastim Biosimilar Revenue (2021-2032)
- 7.2.2 North America Pegfilgrastim Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Pegfilgrastim Biosimilar Revenue (2021-2032)
- 7.3.2 Europe Pegfilgrastim Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Pegfilgrastim Biosimilar Revenue (2021-2032)
- 7.4.2 Asia-Pacific Pegfilgrastim Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Pegfilgrastim Biosimilar Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Pegfilgrastim Biosimilar Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Biocon
- 8.1.1 Biocon Company Information
- 8.1.2 Biocon Business Overview
- 8.1.3 Biocon Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Biocon Pegfilgrastim Biosimilar Product Portfolio
- 8.1.5 Biocon Recent Developments
- 8.2 Coherus BioSciences
- 8.2.1 Coherus BioSciences Company Information
- 8.2.2 Coherus BioSciences Business Overview
- 8.2.3 Coherus BioSciences Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Coherus BioSciences Pegfilgrastim Biosimilar Product Portfolio
- 8.2.5 Coherus BioSciences Recent Developments
- 8.3 Dr Reddy’s Laboratories
- 8.3.1 Dr Reddy’s Laboratories Company Information
- 8.3.2 Dr Reddy’s Laboratories Business Overview
- 8.3.3 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Dr Reddy’s Laboratories Pegfilgrastim Biosimilar Product Portfolio
- 8.3.5 Dr Reddy’s Laboratories Recent Developments
- 8.4 Intas Pharmaceuticals
- 8.4.1 Intas Pharmaceuticals Company Information
- 8.4.2 Intas Pharmaceuticals Business Overview
- 8.4.3 Intas Pharmaceuticals Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Intas Pharmaceuticals Pegfilgrastim Biosimilar Product Portfolio
- 8.4.5 Intas Pharmaceuticals Recent Developments
- 8.5 Mundipharma International
- 8.5.1 Mundipharma International Company Information
- 8.5.2 Mundipharma International Business Overview
- 8.5.3 Mundipharma International Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Mundipharma International Pegfilgrastim Biosimilar Product Portfolio
- 8.5.5 Mundipharma International Recent Developments
- 8.6 Pfizer
- 8.6.1 Pfizer Company Information
- 8.6.2 Pfizer Business Overview
- 8.6.3 Pfizer Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Pfizer Pegfilgrastim Biosimilar Product Portfolio
- 8.6.5 Pfizer Recent Developments
- 8.7 Mylan
- 8.7.1 Mylan Company Information
- 8.7.2 Mylan Business Overview
- 8.7.3 Mylan Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Mylan Pegfilgrastim Biosimilar Product Portfolio
- 8.7.5 Mylan Recent Developments
- 8.8 Novartis
- 8.8.1 Novartis Company Information
- 8.8.2 Novartis Business Overview
- 8.8.3 Novartis Pegfilgrastim Biosimilar Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Novartis Pegfilgrastim Biosimilar Product Portfolio
- 8.8.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Pegfilgrastim Biosimilar Value Chain Analysis
- 9.1.1 Pegfilgrastim Biosimilar Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Pegfilgrastim Biosimilar Production Mode & Process
- 9.2 Pegfilgrastim Biosimilar Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Pegfilgrastim Biosimilar Distributors
- 9.2.3 Pegfilgrastim Biosimilar Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst